The Medical Advisory Board for Advancing CTNNB1 Cures & Treatments sets the strategic direction for our funded research on CTNNB1 Syndrome.
Wendy K. Chung, M.D., Ph.D.Kennedy Family Professor of Pediatrics and Medicine
Wendy Chung, M.D., Ph.D. is a clinical and molecular geneticist and the Kennedy Family Professor of Pediatrics and Medicine at Columbia University Irving Medical Center. She received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics.
Dr. Chung directs NIH funded research programs in human genetics of autism, neurodevelopmental disorders, birth defects including congenital diaphragmatic hernia and congenital heart disease, pulmonary hypertension, cardiomyopathy, and breast cancer. Her studies to develop and implement inexpensive newborn screening for spinal muscular atrophy have been instrumental in changing the policy to screen every newborn in the US for this genetic condition to ensure access to presymptomatic treatment with gene therapy and oligonucleotide therapy. She leads the Precision Medicine Resource in the Irving Institute at Columbia University. She was the recipient of the American Academy of Pediatrics Young Investigator Award, the Medical Achievement Award from Bonei Olam, and she was awarded the 2018 Academy Medal for Distinguished Contributions in Biomedical Science.
Most recently, Dr. Chung was named an honoree at the National Organization for Rare Disorders (NORD) 2019 Rare Impact Awards for her outstanding work in support of the rare disease community.
Dr. Chung is renowned for her teaching and mentoring and received Columbia University’s highest teaching award, the Presidential Award for Outstanding Teaching. She is well known for her TED talks with millions of views. She was the original plaintiff in the Supreme Court case that overturned the ability to patent genes and the Institute of Medicine Committee on Genetic Testing.
A world leader in the diagnosis and treatment of rare diseases, Dr. Chung has identified more than 38 new genes for human diseases. She is experienced in both the molecular and clinical characterization of the disorders associated with these gene mutations, as well as the integration of these discoveries into clinical practice through the development and implementation of clinical genetic testing in medical care.
Dr. Chung enjoys the challenges of genetics as a rapidly changing field of medicine and strives to facilitate the integration of genetic medicine into all areas of health care in a medically, scientifically, and ethically sound, accessible, and cost effective manner.
H.Y. Edwin Chan, Ph.D.School of Life Sciences at the Chinese University of Hong Kong
Dr. Chan obtained his doctoral degree from the University of Cambridge, UK and postdoctoral training from University of Pennsylvania, USA. His main areas of interest are human disease modelling, cellular, genetic and biochemical analyses of rare neurological diseases.
Eileen StarkClinical Scientist at Cellectis, Clinical-Stage Biopharmaceutical Company
Eileen spent much of her career as a Pediatric Neuro-Oncology Nurse Practitioner in the Division of Pediatric Hematology, Oncology and Stem Cell Transplant at the Children’s Hospital of New York Presbyterian, Columbia University. Most recently, she has taken on the role as a clinical scientist at Cellectis. Cellectis has 20 years of expertise in gene editing.